Startups channel feed – Endpoints News

Startups channel feed

Celgene vet Jackie Fouse grabs the reins of a Vivek Ramaswamy vant-up

8 years ago

Google’s data-crunching mavens at GV buy in to Decibel’s R&D program for hearing loss, tinnitus

8 years ago

Medicxi’s new fund jumps off the beaten biotech path to lead a $30M round for diabetes program

8 years ago

With deep ties to China, Vivace exits stealth mode with a lead cancer program, platform and $40M

8 years ago

Versant carefully sets the stage for a $68M debut of a biotech player focused on synthetic lethality

8 years ago

Langer-backed Sigilon sets sail with $23M and new ‘living’ cell therapy tech

8 years ago

Rubius lands $120M bonanza to fund a groundbreaking pipeline effort on a new drug platform

8 years ago

Art Krieg comes down from the mountain with a $27M round for Checkmate Pharmaceuticals

8 years ago

Little Aziyo is growing a new regenerative med company, led by some familiar faces in the biz

8 years ago

Rising Penn star Saar Gill gets funding for a next-gen CAR-T startup, adding a new weapon to the mix

8 years ago

BRIEF: Deciphera bags a $52M round to back its cancer drug pipeline work

8 years ago

Bicycle Therapeutics banks a $52M B round for the next leg of the long R&D journey ahead

8 years ago

China biotech startup InventisBio bags a $19M round for early-stage R&D

8 years ago

Eli Lilly-backed Symic raises $30M round as it preps for a pivotal trial

8 years ago

Two R&D pros map a PhIII game plan with $65M round and a castoff from Pfizer

8 years ago

After a bruising turn as Sarepta CEO, Chris Garabedian is back in biotech with a new role as godfather to a bunch of startups

8 years ago

Armed with a $435M bankroll, Polaris looks to the next wave of biotech startups

9 years ago

Five months, $98.5M and a PhII drug from Novartis later, Magenta Therapeutics is flooring it

9 years ago

Neil Kumar's BridgeBio lines up subsidiary No. 9 with a $27M shot at TTR amyloidosis

9 years ago

Chalk up one more biotech startup for MIT’s Bob Langer

9 years ago

A serial biotech startup team is back in business, armed with $40M and a focus on NASH

9 years ago

Frequency Therapeutics gets a $32M startup round to help fine tune its hearing loss drug R&D

9 years ago

Novartis finds its next mass-market ophthalmology drug candidate at a small virtual biotech with a global view

9 years ago

Takeda partners with an upstart drugs-from-bugs microbiome player inspired by a fecal transplantation biz

9 years ago

First page Previous page 68 69 707172 73 Next page Last page